Press coverage about vTv Therapeutics (NASDAQ:VTVT) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. vTv Therapeutics earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 47.4543493526532 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of research firms have weighed in on VTVT. Roth Capital began coverage on shares of vTv Therapeutics in a research note on Thursday, March 8th. They set a “buy” rating and a $17.00 price objective for the company. Northland Securities began coverage on shares of vTv Therapeutics in a research note on Thursday, February 8th. They set an “outperform” rating and a $28.00 price objective for the company. Canaccord Genuity set a $15.00 price objective on shares of vTv Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 21st. Zacks Investment Research lowered shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Finally, Seaport Global Securities began coverage on shares of vTv Therapeutics in a research note on Thursday, March 29th. They set a “buy” rating and a $14.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $15.07.
Shares of VTVT stock traded down $0.15 during trading hours on Thursday, reaching $3.69. The company had a trading volume of 163,584 shares, compared to its average volume of 211,860. vTv Therapeutics has a one year low of $3.57 and a one year high of $8.40. The firm has a market capitalization of $132.56, a PE ratio of -2.21 and a beta of 1.74. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of -0.10.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by BBNS and is the property of of BBNS. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/vtv-therapeutics-vtvt-given-media-sentiment-rating-of-0-13/2029262.html.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.